Influenza is a major cause of morbidity for people with significant underlying disease, but the impact of influenza on people infected with human immunodeficiency virus (HIV) remains unclear. We studied a population of HIV-infected adults during the 1998-1999 influenza season to see whether influenza had any adverse effects on the course of HIV infection. During 5 months of follow-up, we found no unique clinical manifestations or negative impact on CD4 + cell count, virus load, or clinical progression of HIV disease. Although half of our cohort received antibiotic therapy, none received specific anti-influenza therapy and none required hospitalization. Acute influenza does not appear to be a risk for progression of HIV disease.
Influenza remains an important cause of morbidity and mortality worldwide. Even though it has been 120 years since the last major pandemic, smaller epidemics have claimed several hundred thousand lives [1] . Traditionally, most deaths are from pneumonia and exacerbations of preexisting cardiopulmonary conditions [2, 3] . It is estimated that up to 90% of those who die are aged у65 years [4] . It remains unclear what the precise impact of HIV infection is on the incidence and course of influenza. Patients already immunocompromised from HIV may be more likely to contract influenza, experience increased severity of illness, and have higher rates of hospitalization [5] . As a result of these concerns, the Advisory Committee on Immunization Practices recommends considering influenza vaccination for patients infected with HIV [1] .
We reviewed our experience with influenza during the 1998-1999 influenza season. Specifically, we studied disease presentation, development of complications, use of antibiotic therapy, and need for hospitalization. Because it has been shown that influenza vaccination may transiently increase HIV virus load [6, 7] , we identified a population of known HIV-infected patients with influenza and looked prospectively to see whether influenza itself had any impact on virus load or HIV disease progression. Given that most influenza deaths are related to underlying disease, we prospectively followed patients to see if there was any detectable increase in the incidence of opportunistic infections after influenza infection.
PATIENTS AND METHODS
The Haelen Center at the Hospital of Saint Raphael (New Haven, CT) provides primary care to ∼350 adults infected with HIV. Case patients were identified by cross-matching a list of all positive influenza direct fluorescent antigen (DFA) tests with known patients seen in the Haelen Center. HIV-infected patients with documented influenza were then prospectively followed for 5 months to watch for development of an opportunistic infection and to measure changes in CD4 ϩ cell counts The following definitions were used. Influenza was defined as an acute febrile respiratory illness with positive DFA obtained from a nasopharyngeal swab. Pneumonia was defined as the presence of a febrile respiratory illness with radiographic evidence of an infiltrate and isolation of a bacterial pathogen from expectorated sputum. Bronchitis was defined as the presence of a productive cough and isolation of a bacterial pathogen from an expectorated sputum specimen, but with no radiographic evidence of pneumonia. Otitis media was defined as the presence of a bulging or inflamed tympanic membrane. Definite sinusitis was defined as a febrile illness characterized by headache, sinus tenderness, and purulent nasal discharge with CT evidence of an air-fluid level. Presumptive sinusitis was the clinical manifestations described above without a CT scan.
RESULTS
During the 1998-1999 community outbreak of influenza, 212 patients seen at the Hospital of Saint Raphael had laboratoryconfirmed influenza. A total of 157 patients required hospitalization, 34 were treated and released from the emergency room, 14 were managed in the outpatient clinics, and 7 health care workers were diagnosed in the employee health department. At least 12 (5.7%) of the 212 patients were known to be infected with HIV.
Among 349 patients with HIV who were followed regularly in the Haelen Center, 158 (45%) received the influenza vaccine (administered September 1998-February 1999). Of the 12 HIVinfected patients diagnosed with influenza, 11 were infected with influenza A virus and 1 with influenza B virus. Of these 12, 7 (58%) had received the influenza vaccine. Reasons for not receiving the vaccination included patient refusal (1 patient), not having been to clinic during the vaccination period (1), and no reason documented (3). One patient was seen in the emergency room and discharged; no patient required hospitalization.
Patient characteristics are shown in table 1. Five patients were women and 7 were men. All patients were taking highly active antiretroviral therapy (HAART). Only 1 patient was not taking a protease inhibitor. Six patients were taking dual protease inhibitors. Table 2 shows the specific antiviral regimens. Table 3 shows the distribution of virus loads and CD4 ϩ cell counts in patients who developed influenza infection. Five patients had virus loads !400 copies/mL, and 2 patients had virus loads 1700,000 copies/mL.
Clinical manifestations were similar to those described in patients without HIV infection. Body temperature of 138.3ЊC was present in 6 of 12 patients. Other clinical manifestations attributed to influenza included cough (12 patients), myalgias (10), tachycardia (5), headache (5), and sore throat (4). We were unable to accurately assess duration of symptoms.
Six patients received antimicrobial therapy for bacterial superinfection. Two patients had bacterial pneumonia, 2 had bronchitis, 1 had otitis media, and 1 had definite sinusitis. Two additional patients had presumptive sinusitis. No patient received amantadine.
Time to development of influenza after vaccination varied widely. Seven patients received the influenza vaccine. One became ill within 60 days of the vaccine, 4 within 90 days, 1 within 120 days, and 1 within 150 days.
Two patients had been started on abacavir (Ziagen [Glaxo Wellcome]) within 2 weeks of becoming ill, which complicated the differential diagnosis. Neither patient had abacavir therapy discontinued, and neither developed the abacavir hypersensitivity syndrome.
Patients with documented influenza were prospectively followed for 5 months. No patient developed an opportunistic infection during this time. One patient developed complications of cirrhosis related to underlying hepatitis C infection and died 3 months later. A second patient was admitted 3 weeks after the diagnosis of influenza for complications of a Hickman catheter and recovered uneventfully.
Two patients had active opportunistic infections at the time influenza was diagnosed. One had disseminated Mycobacterium avium-intracellulare infection and continued to improve with antimicrobial therapy; the second had Toxoplasma encephalitis and remained stable on appropriate therapy. Two patients experienced episodes of known genital herpes, 1 developed oral thrush after beginning antibiotic therapy, and 2 patients developed reactive airway disease immediately after the acute illness, requiring the use of inhaled b-agonists. Table 3 shows follow-up CD4 ϩ cell counts and virus loads.
Virus load data are available for all 12 patients with documented influenza. Six patients experienced a decrease in CD4 ϩ cell count during the observation period, although in most cases the change was small (13-96 cells/mm 3 ; median, 34 cells/mm 3 ). One patient (patient 9) had an increase in virus load from log 10 4.31 to log 10 4.91. He had a long history of poor medication compliance and had discontinued his medications shortly after the diagnosis of influenza.
During the time that our patients infected with HIV were affected by the influenza outbreak (15 January-29 March), 39 other HIV-infected patients were admitted to the Hospital of Saint Raphael. Of these 39, 11 had diagnosed respiratory tract disease: 6 had bacterial pneumonia, 4 Pneumocystis carinii pneumonia, and 1 acute bronchospasm. All were tested and were negative by DFA for influenza.
DISCUSSION
Our results indicate that HIV-infected patients with influenza present with typical symptoms of fever, myalgia, sore throat, and cough. An increased risk of complicated and possibly fatal influenza in patients infected with HIV has been postulated [8] . A retrospective study of HIV-infected women enrolled in Tennessee's Medicaid program found that the attributable risk for cardiopulmonary hospitalizations was increased during the influenza season [9] . The risk for hospitalization in these HIVpositive women was higher than that for women with other underlying illnesses, including those known to increase risk for influenza complications such as chronic heart and lung disease [9] . Other reports suggest that influenza symptoms might be prolonged and that the risk for complications from influenza might be increased for some patients infected with HIV [5, 10] . Our patients all had relatively mild disease, and none received specific antiviral therapy. The time period of this study antedated availability of the neuraminidase inhibitors. Although none of the patients we studied required hospitalization, there was a high use of antibiotics. Six of 12 patients received treatment for bacterial superinfection. Although the extent of antibiotic use may overestimate the risk of bacterial complications, 3 of the 6 treated patients had clear radiographic evidence of disease, and another had clinical bronchitis with a positive sputum culture.
We found no evidence that influenza itself negatively impacts the course of HIV infection. During the 5 months of followup, there were no new opportunistic infections, and no patient experienced even a 1 log 10 increase in HIV viral RNA. Our sample size was extremely small and most subjects had wellcontrolled disease (as evidenced by their baseline virus load and CD4
ϩ cell counts). It is unclear how the use of HAART might have impacted the interaction of HIV and influenza. The role of influenza immunization in patients infected with HIV has been debated in the medical literature because of concerns regarding efficacy, cost-effectiveness, and exacerbation of underlying HIV [11] [12] [13] . Much of the controversy followed a publication by Ho in 1992 [6] , which documented an increase in HIV RNA after influenza vaccination. This increase was determined to be short-lived; the virus load returned to steady state within a matter of weeks [6, 7, 14, 15] . More recent studies have confirmed that influenza vaccination does not substantially impact HIV virus load or CD4 ϩ cell count [13, [16] [17] [18] [19] .
The 1998-1999 influenza vaccine strains were well matched with the circulating virus strains [20] . Although it has previously been shown that individuals with the lowest CD4 ϩ cell counts (especially those !100 cells/mm 3 ) respond poorly to influenza vaccination [13] , most of the patients we saw who failed to respond to vaccine had relatively high CD4 ϩ cell counts (median, 270 cells/mm 3 ). Similarly, data from Fuller et al. [21] suggested that high virus loads might be associated with an impaired immune response to influenza vaccination, although this association was not significant in multivariate analysis.
Although we did not look for serological responses to vaccination, we observed that the patients who developed influenza despite vaccination had relatively low virus loads (only 1 patient, who had a virus load 1log 10 5). Overall, we observed 7 cases of influenza among 158 vaccine recipients infected with HIV.
Interestingly, we saw no evidence of HIV progression in patients who were coinfected with HIV and influenza. Even the patients with active opportunistic infections at the time of influenza infection (1 with disseminated Mycobacterium avium intracellulare infection and 1 with CNS toxoplasmosis) had no complications. Our observations agree with those of Safrin et al. [5] , who studied a group of patients coinfected with influenza and HIV. They found that patients infected with HIV had no unique clinical manifestations and no increase in the rate of secondary complications. Their cohort of patients differed from ours in that 5 of the 6 patients they studied were hospitalized. None of their patients were receiving antiviral therapy.
Our study is limited by sampling bias. We do not know how many of the 212 total patients diagnosed with influenza might actually have been infected with HIV. In addition, there may have been patients from our clinic who sought medical care at other institutions during the influenza season.
In summary, our cohort of patients did well during an influenza outbreak. We found that influenza infection did not adversely affect surrogate markers or HIV progression in a population receiving HAART. Further studies are needed to delineate which patients benefit from routine influenza immunization and to define a role for use of the new neuraminidase inhibitors.
